Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

134.33
Delayed Data
As of 4:00pm ET
 +4.02 / +3.08%
Today’s Change
73.41
Today|||52-Week Range
153.15
+33.97%
Year-to-Date
Better Days Ahead for the Pharma Sector?
3:20pm / Zacks.com - Paid Partner Content
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data
Jun 21 / Zacks.com - Paid Partner Content
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
Jun 22 / Zacks.com - Paid Partner Content
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
Jun 21 / Zacks.com - Paid Partner Content
Geode Capital Management, Llc Buys Abbott Laboratories, TechnipFMC PLC, GGP Inc, Sell...
Jun 21 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close130.31
Today’s open130.41
Day’s range129.61 - 135.28
Volume1,261,685
Average volume (3 months)2,548,379
Market cap$26.7B
Dividend yield--
Data as of 4:00pm ET, 06/28/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-240.51%
Earnings growth (next 5 years)+98.90%
Revenue growth (last year)+46.70%
P/E ratioNM
Price/Sales17.60
Price/Book58.67

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...+3.70+3.03%
ZTSZoetis Inc+0.19+0.30%
VRTXVertex Pharmaceutica...+1.88+1.45%
MYLMylan NV+0.64+1.67%
Data as of 4:01pm ET, 06/28/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.00
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts